2 Meme Stocks to Avoid in the Healthcare Sector

: CLOV | Clover Health Investments Corp. Cl A News, Ratings, and Charts

CLOV – The popularity of the meme stocks is clearly backed by internet virality. So, these stocks’ dizzying rallies are usually short-lived given the stocks’ typically poor fundamentals. As investors focus now on turnaround industries that are benefiting from the global economic recovery, we believe highly overvalued healthcare meme stocks Clover Health Investments (CLOV) and Sorrento Therapeutics (SRNE) are best avoided.

Meme stocks typically generate investor interest through social media forums, and most of the time their rallies are not backed by strong financials or market technicalities. Given the speculative nature of retail investors and these stocks’ supernormal price gains, they generally retreat following an extended rally.

Meme stocks in the healthcare sector are currently more susceptible to a market crash because investors are focusing on outdoor and cyclical stocks amid the fast-paced economic recovery.

So, we think healthcare stocks Clover Health Investments, Corp. (CLOV) and Sorrento Therapeutics, Inc. (SRNE), which are currently surging on the meme stock craze, are best avoided now.

Click here to checkout our Healthcare Sector Report for 2021

Clover Health Investments, Corp. (CLOV)

CLOV is a Medicare Advantage (MA) insurer in the United States. Its MA plans include hospital coverage, doctor visits, and drug coverage, vision, dental, and hearing coverage. CLOV is based in Franklin, Tenn.

On April 6, Kaskela Law LLC announced the filing of a shareholder class action lawsuit against CLOV. alleging alleged deceptive financial reporting.

CLOV’s revenue increased 21% year-over-year to $200.33 million in the fiscal first quarter, ended March 31. However, its loss from operations increased 347.2% year-over-year to $119.09 million. Its net loss increased 71.9% from its  year-ago value to $48.42 million.

A $819.22 million consensus revenue estimate for the current year indicates a 21.7% increase year-over-year. Analysts expect the company’s EPS to remain negative until at least 2022. CLOV has gained 74.9% over the past month and 5.8% over the past five days.

CLOV has an overall F rating, which equates to Strong Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with the weighting of each optimized to improve overall performance.

It also has an F grade for Value, Stability, and Sentiment, and a D grade for Growth and Quality. Among the 11 stocks in the Medical – Health Insurance industry, CLOV is ranked  last. To see more of CLOV’s component grades, click here.

Sorrento Therapeutics, Inc. (SRNE)

SRNE is a clinical-stage and commercial biopharma company that develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The San Diego-based Company operates through two segments: Sorrento Therapeutics and Scilex.

On June 11, SRNE announced the Medicines and Healthcare products Regulatory Agency’s (MHRA) approval for Phase 2 Clinical Trial for SRNE’s COVI-DROPS product candidate. However, it is uncertain whether the product will win final approval, and even if it does, it might take a while for SRNE to generate revenues from the drug.

SRNE’s total revenue increased 84.6% year-over-year to $14.26 million in its  fiscal first quarter, ended March 31. Its loss from operations grew 96.7% from its  year-ago value to $84.91 million, while its net income stood at $2.42 million, indicating a 103.5% improvement from a $69.18 million loss  in the same period last year.

Analysts expect SRNE’s revenues to increase 53.9% year-over-year to $13.86 million in the current quarter, ending June 2021. However, the company’s EPS is expected to remain negative at least in the current year.

Shares of SRNE have gained 58.8% over the past year. The stock  lost 2% intraday to close yesterday’s trading session at $9.70.

It is no surprise that SRNE has an overall D rating, which equates to Sell in our proprietary POWR Ratings system.

The stock also has a D grade for Momentum, Stability, Sentiment, and Quality. Among the 494 stocks in the F-rated Biotech industry, SRNE is ranked #391. To see additional SRNE Ratings for Growth and Value, click here.

Click here to checkout our Healthcare Sector Report for 2021


CLOV shares rose $0.04 (+0.30%) in after-hours trading Wednesday. Year-to-date, CLOV has declined -20.57%, versus a 15.24% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CLOVGet RatingGet RatingGet Rating
SRNEGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

2022 Stock Market Outlook

The stock market (SPY) has continued on a bullish path in 2021. Will that continue in 2022? And what could happen to awaken the bear market from hibernation? 40 year investment veteran Steve Reitmeister explores this and more in this early edition of his 2022 Stock Market Outlook. Read on for full details below...

:  |  News, Ratings, and Charts

How Recent Bearish Sentiment Will Impact the Stock Market

Last week, the S&P 500 (SPY) fell during a short trading week. Multiple factors were weighing on investor sentiment. First was September's history for being a weaker month for stock performance. In addition, the previous week's August payrolls miss seemed to linger on investors' minds due to concerns that the delta variant of COVID was slowing the rebound in the economy. The real estate sector led declines as long-term interest rates increased. Consumer staples and utility stocks performed the best. In terms of market cap, the small-cap Russell 2000 Index underperformed the market after two strong weeks of outperforming the larger benchmarks. Growth stocks also outperformed Value stocks. I’ll discuss this and more below…

:  |  News, Ratings, and Charts

How to Turn Low Priced Stocks into BIG Winners?

Some investors are into growth stocks...some prefer value stocks while others are into momentum, income, chart patterns, insider trading and more. But one area that most investors agree upon is the great appeal in buying low priced stocks. Like those under $10 given the potential that prices soar and you easily beat the stock market (SPY). Read on to discover our brand new strategy for selecting low priced stocks that has led to a surprising +62.88% average annual return. Get the rest below...

:  |  News, Ratings, and Charts

3 Growth Stocks You Can Buy at a Reasonable Price

Even with growth stocks falling last week, investors are still pouring money into companies with strong growth potential. When you add in a value component, you get the best of both worlds. That's why investors should consider growth at a reasonable price stocks such as Westlake Chemical Corporation (WLK), ManpowerGroup (MAN), AutoNation, Inc. (AN).

:  |  News, Ratings, and Charts

How to Turn Low Priced Stocks into BIG Winners?

Some investors are into growth stocks...some prefer value stocks while others are into momentum, income, chart patterns, insider trading and more. But one area that most investors agree upon is the great appeal in buying low priced stocks. Like those under $10 given the potential that prices soar and you easily beat the stock market (SPY). Read on to discover our brand new strategy for selecting low priced stocks that has led to a surprising +62.88% average annual return. Get the rest below...

Read More Stories

More Clover Health Investments Corp. Cl A (CLOV) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLOV News